Coronavirus Vaccine Market
Coronavirus Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type (Repurposed Vaccines, Inactivated Virus, Non-replicating Viral Vector, Protein Subunit, DNA Vaccine and RNA Vaccine), Age Group (12 to 18 and Above 18), Route of Administration, Distribution Channel, Technology and By Geography
Years Covered |
2021-2030 |
Estimated Year Value (2023) |
US $43.9 BN |
Projected Year Value (2030) |
US $82.3 BN |
CAGR (2023 - 2030) |
9.4% |
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
Largest Market |
North America |
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Coronavirus Vaccine Market is accounted for $43.9 billion in 2023 and is expected to reach $82.3 billion by 2030 growing at a CAGR of 9.4% during the forecast period. A Coronavirus Vaccine is a medical substance developed to provide immunity against the novel coronavirus, SARS-CoV-2, which causes COVID-19. It stimulates the body's immune system to recognize and neutralize the virus, preventing infection or reducing the severity of symptoms if exposure occurs. Most vaccines target the virus's spike protein, which it uses to enter human cells. Different types of vaccines, including mRNA, viral vector, protein subunit, and inactivated virus vaccines, have been developed and authorized for emergency use globally.
According to the National Institutes of Health (NIH), the Pfizer-BioNTech COVID-19 vaccine received FDA approval for commercialization on 23 August 2021.
Market Dynamics:
Driver:
Urgent global need
The COVID-19 pandemic had unprecedented global impact, causing widespread illness, death, economic disruption, and social upheaval. Vaccines are recognized as a critical tool in controlling the spread of the virus, reducing the burden on healthcare systems, and ultimately saving lives. Moreover, governments, healthcare organizations, and the public are acutely aware of the urgency to develop, produce, and distribute vaccines on a massive scale. The urgency is further heightened by the emergence of new variants of the virus, emphasizing the need for continued vigilance and adaptation in vaccine development, which has accelerated market demand.
Restraint:
Manufacturing constraints
The rapid global demand for COVID-19 vaccines has strained manufacturing capacities, leading to supply shortages, delays in production, and distribution challenges. Several factors contribute to these constraints, including the complexity of vaccine production processes, limited manufacturing facilities equipped for vaccine production, and shortages of raw materials and specialized equipment. Additionally, shortages of critical components, such as lipid nanoparticles used in mRNA vaccine formulations, can disrupt manufacturing timelines and limit production capacity. As a result, manufacturing constraints are a significant factor hampering market demand.
Opportunity:
Government support
With the COVID-19 pandemic posing unprecedented public health challenges, governments worldwide have mobilized substantial resources, funding, and regulatory support to accelerate vaccine development, production, and distribution efforts. Additionally, governments have provided financial investments, research grants, and incentives to pharmaceutical companies and research institutions to expedite vaccine development timelines and scale up manufacturing capacity. Therefore, government support is a factor propelling market demand.
Threat:
Vaccine efficacy and safety concerns
Vaccine efficacy and safety concerns represent a significant restraint in the coronavirus vaccine market. Concerns regarding vaccine efficacy relate to how well a vaccine prevents infection or reduces the severity of the disease. Additionally, safety concerns regarding vaccines encompass potential adverse reactions, side effects, or long-term health implications. Reports of rare but serious adverse events following vaccination, such as blood clotting disorders or myocarditis, have raised concerns, eroded public confidence in vaccine safety, and impacted market growth.
Covid-19 Impact
The impact of COVID-19 on the coronavirus vaccine market has been profound and multifaceted. COVID-19 spurred unprecedented collaboration among scientists, researchers, pharmaceutical companies, and governments to accelerate vaccine development timelines. Moreover, the pandemic necessitated the rapid deployment of innovative vaccine technologies, such as mRNA and viral vector platforms, leading to the development and approval of multiple COVID-19 vaccines in record time.
The RNA vaccine segment is expected to be the largest during the forecast period
The RNA vaccine segment is estimated to hold the largest share. These vaccines utilize a novel technology based on messenger RNA (mRNA) to instruct cells in the body to produce a viral protein, triggering an immune response against the virus. The development of RNA vaccines offers several advantages, including rapid production and scalability. Additionally, RNA vaccines can be easily modified to target new variants of the virus by updating the mRNA sequence to match emerging strains, enhancing their versatility and adaptability in combating the evolving nature of the pandemic.
The recombinant vaccines segment is expected to have the highest CAGR during the forecast period
The recombinant vaccines segment is anticipated to have lucrative growth during the forecast period. These vaccines are developed using recombinant DNA technology, where specific genes from the SARS-CoV-2 virus, such as those encoding the spike protein, are inserted into host cells, such as yeast or mammalian cells, to produce viral proteins. Recombinant vaccines do not contain live virus particles, eliminating the risk of causing disease. This makes them suitable for individuals with compromised immune systems or other health conditions. Furthermore, recombinant vaccine production is highly scalable and can be rapidly scaled up to meet global demand.
Region with largest share:
North America commanded the largest market share during the extrapolated period. North America has been at the forefront of vaccine innovation, with several leading pharmaceutical companies headquartered in the region spearheading the development of COVID-19 vaccines. These companies have leveraged cutting-edge technologies, such as mRNA and recombinant DNA, to rapidly develop vaccines with high efficacy and safety profiles. Furthermore, governments in North America have provided substantial financial investments, regulatory support, and procurement initiatives to expedite vaccine development and ensure widespread access to vaccines for their populations.
Region with highest CAGR:
Asia Pacific is expected to witness profitable growth over the projection period, due to its large population, diverse healthcare landscape, and emerging economies. China and India, in particular, have emerged as key players in vaccine manufacturing, producing large quantities of COVID-19 vaccines for domestic use and global distribution. These countries have leveraged their manufacturing capabilities and extensive vaccine production infrastructure to supply vaccines to both domestic and international markets. Moreover, several countries in the Asia-Pacific region have actively participated in vaccine research and development, contributing to the global effort to combat the pandemic.
Key players in the market
Some of the key players in the Coronavirus Vaccine Market include Moderna, AstraZeneca, Sinopharm, Pfizer-BioNTech, Sinovac, Johnson & Johnson, Serum Institute of India, Bharat Biotech, Gamaleya Research Institute, Novavax, CureVac, CanSino Biologics, Sanofi-GSK, GlaxoSmithKline and Entos Pharmaceuticals.
Key Developments:
In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.
In July 2023, AstraZeneca, a global biopharmaceutical company, announced collaboration with Absci Corporation. This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.
In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.
In April 2020, Johnson & Johnson announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate.
Vaccine Types Covered:
• Repurposed Vaccines
• Inactivated Virus
• Non-replicating Viral Vector
• Protein Subunit
• DNA Vaccine
• RNA Vaccine
Age Groups Covered:
• 12 to 18
• Above 18
Route of Administrations Covered:
• Intradermal
• Intramuscular
• Intranasal
• Other Route of Administrations
Distribution Channels Covered:
• Hospitals and Clinics
• Government Entities
• Vaccination Centers
• Other Distribution Channels
Technologies Covered:
• Synthetic Vaccines
• Recombinant Vaccines
• Live Attenuated Vaccines
• Conventional Vaccines
• Other Technologies
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Coronavirus Vaccine Market, By Vaccine Type
5.1 Introduction
5.2 Repurposed Vaccines
5.3 Inactivated Virus
5.4 Non-replicating Viral Vector
5.5 Protein Subunit
5.6 DNA Vaccine
5.7 RNA Vaccine
6 Global Coronavirus Vaccine Market, By Age Group
6.1 Introduction
6.2 12 to 18
6.3 Above 18
7 Global Coronavirus Vaccine Market, By Route of Administration
7.1 Introduction
7.2 Synthetic Vaccines
7.3 Intradermal
7.4 Intramuscular
7.5 Intranasal
7.6 Other Route of Administrations
8 Global Coronavirus Vaccine Market, By Distribution Channel
8.1 Introduction
8.2 Hospitals and Clinics
8.3 Government Entities
8.4 Vaccination Centers
8.5 Other Distribution Channels
9 Global Coronavirus Vaccine Market, By Technology
9.1 Introduction
9.2 Synthetic Vaccines
9.3 Recombinant Vaccines
9.4 Live Attenuated Vaccines
9.5 Conventional Vaccines
9.6 Other Technologies
10 Global Coronavirus Vaccine Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Moderna
12.2 AstraZeneca
12.3 Sinopharm
12.4 Pfizer-BioNTech
12.5 Sinovac
12.6 Johnson & Johnson
12.7 Serum Institute of India
12.8 Bharat Biotech
12.9 Gamaleya Research Institute
12.10 Novavax
12.11 CureVac
12.12 CanSino Biologics
12.13 Sanofi-GSK
12.14 GlaxoSmithKline
12.15 Entos Pharmaceuticals
List of Tables
1 Global Coronavirus Vaccine Market Outlook, By Region (2021-2030) ($MN)
2 Global Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
3 Global Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
4 Global Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
5 Global Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
6 Global Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
7 Global Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
8 Global Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
9 Global Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
10 Global Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
11 Global Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
12 Global Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
13 Global Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
14 Global Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
15 Global Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
16 Global Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
17 Global Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
18 Global Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
19 Global Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
20 Global Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
21 Global Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
22 Global Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
23 Global Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
24 Global Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
25 Global Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
26 Global Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
27 Global Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
28 North America Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
29 North America Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
30 North America Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
31 North America Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
32 North America Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
33 North America Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
34 North America Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
35 North America Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
36 North America Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
37 North America Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
38 North America Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
39 North America Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
40 North America Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
41 North America Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
42 North America Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
43 North America Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
44 North America Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
45 North America Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
46 North America Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
47 North America Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
48 North America Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
49 North America Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
50 North America Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
51 North America Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
52 North America Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
53 North America Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
54 North America Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
55 Europe Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
56 Europe Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
57 Europe Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
58 Europe Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
59 Europe Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
60 Europe Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
61 Europe Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
62 Europe Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
63 Europe Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
64 Europe Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
65 Europe Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
66 Europe Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
67 Europe Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
68 Europe Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
69 Europe Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
70 Europe Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
71 Europe Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
72 Europe Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
73 Europe Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
74 Europe Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
75 Europe Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
76 Europe Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
77 Europe Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
78 Europe Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
79 Europe Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
80 Europe Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
81 Europe Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
82 Asia Pacific Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
83 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
84 Asia Pacific Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
85 Asia Pacific Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
86 Asia Pacific Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
87 Asia Pacific Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
88 Asia Pacific Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
89 Asia Pacific Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
90 Asia Pacific Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
91 Asia Pacific Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
92 Asia Pacific Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
93 Asia Pacific Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
94 Asia Pacific Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
95 Asia Pacific Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
96 Asia Pacific Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
97 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
98 Asia Pacific Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
99 Asia Pacific Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
100 Asia Pacific Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
101 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
102 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
103 Asia Pacific Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
104 Asia Pacific Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
105 Asia Pacific Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
106 Asia Pacific Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
107 Asia Pacific Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
108 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
109 South America Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
110 South America Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
111 South America Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
112 South America Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
113 South America Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
114 South America Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
115 South America Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
116 South America Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
117 South America Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
118 South America Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
119 South America Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
120 South America Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
121 South America Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
122 South America Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
123 South America Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
124 South America Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
125 South America Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
126 South America Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
127 South America Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
128 South America Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
129 South America Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
130 South America Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
131 South America Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
132 South America Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
133 South America Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
134 South America Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
135 South America Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
136 Middle East & Africa Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
137 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
138 Middle East & Africa Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
139 Middle East & Africa Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
140 Middle East & Africa Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
141 Middle East & Africa Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
142 Middle East & Africa Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
143 Middle East & Africa Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
144 Middle East & Africa Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
145 Middle East & Africa Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
146 Middle East & Africa Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
147 Middle East & Africa Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
148 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
149 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
150 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
151 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
152 Middle East & Africa Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
153 Middle East & Africa Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
154 Middle East & Africa Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
155 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
156 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
157 Middle East & Africa Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
158 Middle East & Africa Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
159 Middle East & Africa Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
160 Middle East & Africa Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
161 Middle East & Africa Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
162 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.